Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Roy, Somak ^a   Smith, Matthew A ^a   Cieply, Kathy M ^a   Acquafondata, Marie B ^a   Parwani, Anil V ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Division of Pathology Informatics   (United States)

Author keywords

Adenocarcinoma; Beta catenin; Bladder; Colorectal; E cadherin; Metastatic; Primary

Indexed keywords

ACTIN BINDING PROTEIN; BETA CATENIN; CADHERIN; CDH1 PROTEIN, HUMAN; CDX2 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; CYTOKERATIN 20; CYTOKERATIN 7; HOMEODOMAIN PROTEIN; KRT20 PROTEIN, HUMAN; KRT7 PROTEIN, HUMAN; TUMOR MARKER; VILLIN;

ADENOCARCINOMA; AGED; ARTICLE; BLADDER TUMOR; CHEMISTRY; CHROMOSOME ABERRATION; COLORECTAL TUMOR; DIFFERENTIAL DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; HUMAN CHROMOSOME; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-20; KERATIN-7; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84868247991     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-151     Document Type: Article

References (26)

1. Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991, 67:2165-2172. 10.1002/1097-0142(19910415)67:8<2165::AID-CNCR2820670827>3.0.CO;2-M, 1706216.
2. Thomas AA, Stephenson AJ, Campbell SC, Jones JS, Hansel DE. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol 2009, 40:108-116. 10.1016/j.humpath.2008.06.022, 18789486.
3. Wang HL, Lu DW, Yerian LM, Alsikafi N, Steinberg G, Hart J, Yang XJ. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001, 25:1380-1387. 10.1097/00000478-200111000-00005, 11684954.
4. Anderstrom C, Johansson SL, von Schultz L. Primary adenocarcinoma of the urinary bladder. A clinicopathologic and prognostic study. Cancer 1983, 52:1273-1280. 10.1002/1097-0142(19831001)52:7<1273::AID-CNCR2820520724>3.0.CO;2-7, 6883290.
5. Jones WA, Gibbons RP, Correa RJ, Cummings KB, Mason JT. Primary adenocarcinoma of bladder. Urology 1980, 15:119-122. 10.1016/0090-4295(80)90400-8, 7355534.
6. Nocks BN, Heney NM, Daly JJ. Primary adenocarcinoma of urinary bladder. Urology 1983, 21:26-29. 10.1016/0090-4295(83)90117-6, 6823700.
7. Epstein JI, Amin MB, Reuter VE. Glandular lesions 2004, Philadelphia: Lippincott Williams & Wilkins.
8. Melicow MM. Tumors of the urinary bladder: a clinico-pathological analysis of over 2500 specimens and biopsies. J Urol 1955, 74:498-521.
9. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol 1984, 131:1-8.
10. Mostofi FK, Thomson RV, Dean AL. Mucous adenocarcinoma of the urinary bladder. Cancer 1955, 8:741-758. 10.1002/1097-0142(1955)8:4<741::AID-CNCR2820080417>3.0.CO;2-C, 13240656.
11. Abol-Enein H, el Mekresh MM, el Baz MA, Abol-Enein H, Ghoneim MA. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol 1998, 82:206-212. 10.1046/j.1464-410X.1998.00718.x, 9722755.
12. Shaaban AA, Elbaz MA, Tribukait B. Primary nonurachal adenocarcinoma in the bilharzial urinary bladder: deoxyribonucleic acid flow cytometric and morphologic characterization in 93 cases. Urology 1998, 51:469-476. 10.1016/S0090-4295(97)00637-7, 9510355.
13. Sung MT, Lopez-Beltran A, Eble JN, MacLennan GT, Tan PH, Montironi R, Jones TD, Ulbright TM, Blair JE, Cheng L. Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol 2006, 19:1395-1401.
14. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 2009, 33:659-668. 10.1097/PAS.0b013e31819aa4ae, 19252435.
15. Raspollini MR, Nesi G, Baroni G, Girardi LR, Taddei GL. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. Appl Immunohistochem Mol Morphol 2005, 13:358-362. 10.1097/01.pai.0000136552.44045.0f, 16280666.
16. Suh N, Yang XJ, Tretiakova MS, Humphrey PA, Wang HL. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005, 18:1217-1222. 10.1038/modpathol.3800407, 15803184.
17. Tamboli P, Mohsin SK, Hailemariam S, Amin MB. Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel. Arch Pathol Lab Med 2002, 126:1057-1063.
18. Del Sordo R, Bellezza G, Colella R, Mameli MG, Sidoni A, Cavaliere A. Primary signet-ring cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 5 cases. Appl Immunohistochem Mol Morphol 2009, 17:18-22. 10.1097/PAI.0b013e31816a7466, 18698262.
19. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000, 119:854-865. 10.1053/gast.2000.16507, 10982779.
20. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790. 10.1126/science.275.5307.1787, 9065402.
21. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Cook RJ, Little NS, Robinson BG, Clifton-Bligh RJ, McDonald KL. Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Endocrinol Metab 2009, 94:1436-1442. 10.1210/jc.2008-2075, 19158195.
22. Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RJ, Wheeler TM, Lerner SP. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001, 165:1473-1479. 10.1016/S0022-5347(05)66330-6, 11342899.
23. Chetty R, Serra S, Asa SL. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol 2008, 32:413-419. 10.1097/PAS.0b013e31813547f8, 18300809.
24. Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R, Woodgett JR. Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol 2008, 21:271-281. 10.1038/modpathol.3800990, 18084253.
25. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003, 27:303-310. 10.1097/00000478-200303000-00003, 12604886.
26. Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol 2008, 130:552-559. 10.1309/DFJUHY3WPC9GUU2W, 18794047.